Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. World Most cancers Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 International locations. CA Most cancers J Clin. 2021;71:209–49.
Spella M, Stathopoulos GT. Immune Resistance in Lung Adenocarcinoma. Cancers (Basel). 2021;13:384.
Senosain MF, Massion PP. Intratumor Heterogeneity in Early Lung Adenocarcinoma. Entrance Oncol. 2020;10:349.
Seguin L, Durandy M, Feral CC. Lung Adenocarcinoma Tumor Origin: A Information for Personalised Medication. Cancers (Basel). 2022;14:1759.
Diaz-Cano SJ. Tumor heterogeneity: mechanisms and bases for a dependable utility of molecular marker design. Int J Mol Sci. 2012;13:1951–2011.
Siegel RL, Miller KD, Jemal A. Most cancers statistics, 2016. CA Most cancers J Clin. 2016;66:7–30.
Chatterjee S. Artefacts in histopathology. J Oral Maxillofac Pathol. 2014;18:S111–6.
Hillman H. Limitations of medical and organic histology. Med Hypotheses. 2000;54:553–64.
Taqi SA, Sami SA, Sami LB, Zaki SA. A evaluate of artifacts in histopathology. J Oral Maxillofac Pathol. 2018;22:279.
D’Ambrosi S, Giannoukakos S, Antunes-Ferreira M, Pedraz-Valdunciel C, Bracht JWP, Potie N, et al. Combinatorial Blood Platelets-Derived circRNA and mRNA Signature for Early-Stage Lung Most cancers Detection. Int J Mol Sci. 2023;24:4881.
Ye XD, Zhang N, Jin YX, Xu B, Guo CY, Wang XQ, et al. Dramatically modified immune-related molecules as early diagnostic biomarkers of non-small cell lung most cancers. Febs J. 2020;287:783–99.
Freitas C, Sousa C, Machado F, Serino M, Santos V, Cruz-Martins N, et al. The Function of Liquid Biopsy in Early Prognosis of Lung Most cancers. Entrance Oncol. 2021;11:634316.
Li Y, Solar N, Lu Z, Solar S, Huang J, Chen Z, et al. Prognostic various mRNA splicing signature in non-small cell lung most cancers. Most cancers Lett. 2017;393:40–51.
Li R, Yang YE, Yin YH, Zhang MY, Li H, Qu YQ. Methylation and transcriptome evaluation reveal lung adenocarcinoma-specific diagnostic biomarkers. J Transl Med. 2019;17:324.
Solar L, Zhang Z, Yao Y, Li WY, Gu J. Evaluation of expression variations of immune genes in non-small cell lung most cancers primarily based on TCGA and ImmPort knowledge units and the applying of a prognostic mannequin. Ann Transl Med. 2020;8:550.
Kim N, Kim HK, Lee Okay, Hong Y, Cho JH, Choi JW, et al. Single-cell RNA sequencing demonstrates the molecular and mobile reprogramming of metastatic lung adenocarcinoma. Nat Commun. 2020;11:2285.
Ma KY, Schonnesen AA, Brock A, Van Den Berg C, Eckhardt SG, Liu Z, et al. Single-cell RNA sequencing of lung adenocarcinoma reveals heterogeneity of immune response-related genes. JCI Perception. 2019;4:121387.
Zavidij O, Haradhvala NJ, Mouhieddine TH, Sklavenitis-Pistofidis R, Cai S, Reidy M, et al. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor levels of a number of myeloma. Nat Most cancers. 2020;1:493–506.
Lu T, Yang X, Shi Y, Zhao M, Bi G, Liang J, et al. Single-cell transcriptome atlas of lung adenocarcinoma featured with floor glass nodules. Cell Discov. 2020;6:69.
Olsen TK, Baryawno N. Introduction to Single-Cell RNA Sequencing. Curr Protoc Mol Biol. 2018;122:e57.
Hao Y, Hao S, Andersen-Nissen E, Mauck WM third, Zheng S, et al. Built-in evaluation of multimodal single-cell knowledge. Cell. 2021;184:3573–3587.e29.
Staff RC. R: A language and setting for statistical computing. 2013.
Liaw A, Wiener M. Classification and regression by randomForest. R N. 2002;2:18–22.
Rousseaux S, Debernardi A, Jacquiau B, Vitte AL, Vesin A, Nagy-Mignotte H, et al. Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med. 2013;5:186ra66.
Mitchell KA, Zingone A, Toulabi L, Boeckelman J, Ryan BM. Comparative Transcriptome Profiling Reveals Coding and Noncoding RNA Variations in NSCLC from African Individuals and European Individuals. Clin Most cancers Res. 2017;23:7412–25.
Landi MT, Dracheva T, Rotunno M, Figueroa JD, Liu H, Dasgupta A, et al. Gene expression signature of cigarette smoking and its position in lung adenocarcinoma improvement and survival. PLoS One. 2008;3:e1651.
Su LJ, Chang CW, Wu YC, Chen KC, Lin CJ, Liang SC, et al. Choice of DDX5 as a novel inner management for Q-RT-PCR from microarray knowledge utilizing a block bootstrap re-sampling scheme. BMC Genomics. 2007;8:140.
Lu TP, Tsai MH, Lee JM, Hsu CP, Chen PC, Lin CW, et al. Identification of a novel biomarker, SEMA5A, for non-small cell lung carcinoma in nonsmoking girls. Most cancers Epidemiol Biomark Prev. 2010;19:2590–7.
Sheng M, Xie X, Wang J, Gu W. A Pathway-Primarily based Technique to Establish Biomarkers for Lung Most cancers Prognosis and Prognosis. Evol Bioinform On-line. 2019;15:1176934319838494.
Zhang BZ, Wang YD, Zhou XZ, Zhang Z, Ju HY, Diao XQ, et al. Building of a Prognostic and Early Prognosis Mannequin for LUAD Primarily based on Necroptosis Gene Signature and Exploration of Immunotherapy Potential. Cancers. 2022;14:5153.
Chen Q, Wang XY, Hu J. Systematically integrative evaluation identifies diagnostic and prognostic candidates and small-molecule medication for lung adenocarcinoma. Transl Most cancers Res. 2021;10:3619–46.
Cai SH, Guo XT, Huang CJ, Deng YJ, Du LD, Liu WY, et al. Integrative evaluation and experiments to discover angiogenesis regulators correlated with poor prognosis, immune infiltration and most cancers development in lung adenocarcinoma. J Transl Med. 2021;19:361.
Okayama H, Kohno T, Ishii Y, Shimada Y, Shiraishi Okay, Iwakawa R, et al. Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Most cancers Res. 2012;72:100–11.
Tomida S, Takeuchi T, Shimada Y, Arima C, Matsuo Okay, Mitsudomi T, et al. Relapse-related molecular signature in lung adenocarcinomas identifies sufferers with dismal prognosis. J Clin Oncol. 2009;27:2793–9.
Schabath MB, Welsh EA, Fulp WJ, Chen L, Teer JK, Thompson ZJ, et al. Differential affiliation of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. Oncogene. 2016;35:3209–16.
Therneau T. A bundle for survival evaluation in S. R bundle model, 2015. 2.
Kassambara, A, Kosinski M, Biecek P, Fabian S. Survminer: Drawing Survival Curves Utilizing Ggplot2. 2021. https://CRAN.R-project.org/bundle=survminer. R bundle model 0.4, 2021. 9.
Sturm G, Finotello F, Listing M. Immunedeconv: An R Package deal for Unified Entry to Computational Strategies for Estimating Immune Cell Fractions from Bulk RNA-Sequencing Knowledge. Strategies Mol Biol. 2020;2120:223–32.
Yoshihara Okay, Kim H, Verhaak R. estimate: Estimate of Stromal and Immune Cells in Malignant Tumor Tissues from Expression Knowledge. R bundle model, 2016. 1: p. r21.
Fu J, Li Okay, Zhang W, Wan C, Zhang J, Jiang P, et al. Giant-scale public knowledge reuse to mannequin immunotherapy response and resistance. Genome Med. 2020;12:21.
Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion predict most cancers immunotherapy response. Nat Med. 2018;24:1550–8.
Wong KY, Cheung AH, Chen B, Chan WN, Yu J, Lo KW, et al. Most cancers-associated fibroblasts in nonsmall cell lung most cancers: From molecular mechanisms to medical implications. Int J Most cancers. 2022;151:1195–215.
Xiang H, Ramil CP, Hai J, Zhang C, Wang H, Watkins AA, et al. Most cancers-Related Fibroblasts Promote Immunosuppression by Inducing ROS-Producing Monocytic MDSCs in Lung Squamous Cell Carcinoma. Most cancers Immunol Res. 2020;8:436–50.
Wang L, Cao L, Wang H, Liu B, Zhang Q, Meng Z, et al. Most cancers-associated fibroblasts improve metastatic potential of lung most cancers cells via IL-6/STAT3 signaling pathway. Oncotarget. 2017;8:76116–28.
Scholl C, Frohling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, et al. Artificial Deadly Interplay between Oncogenic KRAS Dependency and STK33 Suppression in Human Most cancers Cells. Cell. 2009;137:821–34.
The Human Protein Atlas. 2022; Out there from: http://www.proteinatlas.org.
Thul PJ, Akesson L, Wiking M, Mahdessian D, Geladaki A, Ait Blal H, et al. A subcellular map of the human proteome. Science. 2017;356:eaal3321.
Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347:1260419.
Wang T, Hao D, Yang S, Ma J, Yang W, Zhu Y, et al. miR-211 facilitates platinum chemosensitivity by blocking the DNA harm response (DDR) in ovarian most cancers. Cell Dying Dis. 2019;10:495.
Zhao DD, Zhao X, Li WT. Identification of differentially expressed metastatic genes and their signatures to foretell the general survival of uveal melanoma sufferers by bioinformatics evaluation. Int J Ophthalmol. 2020;13:1046–53.
Zhang D, Park D, Zhong Y, Lu Y, Rycaj Okay, Gong S, et al. Stem cell and neurogenic gene-expression profiles hyperlink prostate basal cells to aggressive prostate most cancers. Nat Commun. 2016;7:10798.
Wang YX, Marino-Enriquez A, Bennett RR, Zhu MJ, Shen YP, Eilers G, et al. Dystrophin is a tumor suppressor in human cancers with myogenic applications. Nat Genet. 2014;46:601–6.
Ding Z, Zu S, Gu J. Evaluating the molecule-based prediction of medical drug responses in most cancers. Bioinformatics. 2016;32:2891–5.
